KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Common Equity (2016 - 2026)

Moderna (MRNA) has disclosed Common Equity for 11 consecutive years, with $7.4 billion as the latest value for Q1 2026.

  • For Q1 2026, Common Equity fell 26.41% year-over-year to $7.4 billion; the TTM value through Mar 2026 reached $7.4 billion, down 26.41%, while the annual FY2025 figure was $8.6 billion, 20.65% down from the prior year.
  • Common Equity hit $7.4 billion in Q1 2026 for Moderna, down from $8.6 billion in the prior quarter.
  • Across five years, Common Equity topped out at $19.1 billion in Q4 2022 and bottomed at $7.4 billion in Q1 2026.
  • Average Common Equity over 5 years is $13.4 billion, with a median of $12.8 billion recorded in 2024.
  • Year-over-year, Common Equity soared 344.89% in 2022 and then plummeted 32.05% in 2024.
  • Moderna's Common Equity stood at $19.1 billion in 2022, then fell by 27.55% to $13.9 billion in 2023, then decreased by 21.32% to $10.9 billion in 2024, then dropped by 20.65% to $8.6 billion in 2025, then decreased by 14.36% to $7.4 billion in 2026.
  • According to Business Quant data, Common Equity over the past three periods came in at $7.4 billion, $8.6 billion, and $9.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.